Schedule 13G ownership disclosure
Protalix BioTherapeutics Inc
Security class unavailable · CUSIP: 74365A309
Event date: Unavailable
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 2,414,487
- Percent of class
- 5.0300%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-22-001698
- Form type
- SC 13G
- Filer
- HIGHBRIDGE CAPITAL MANAGEMENT LLC
- CIK
- CIK 919185
- Filed
- Feb 14, 2022
- Reporting period
- —
- Description
- Schedule 13G beneficial ownership